Indonesia Oncology Clinical Trials Market Report 2022 to 2030

Indonesia Oncology Clinical Trials Market Analysis

$ 3999

Indonesia's oncology clinical trials market is projected to grow from $75.9 Mn in 2022 to $116.5 Mn by 2030, registering a CAGR of 5.5% during the forecast period of 2022-30. The market will be driven by the increasing need for innovative and effective therapies with the rising incidence of cancers and increased investments in healthcare infrastructure. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Novartis International AG & Kalbe Farma.

ID: IN10IDCT006 CATEGORY: Clinical Trials GEOGRAPHY: Indonesia AUTHOR: Vidhi Upadhyay

Buy Now

Indonesia Oncology Clinical Trials Market Executive Summary

Indonesia's oncology clinical trials market is projected to grow from $75.9 Mn in 2022 to $116.5 Mn by 2030, registering a CAGR of 5.5% during the forecast period of 2022-30. Indonesia is a nation comprised of about 17,000 islands, around 8000 of which are inhabited, with a population of almost 250 Mn people and 300 languages, making it the fourth most populated country in the world. Indonesia has a strong economy, a growing middle class, and a rapidly urbanising population. In Indonesia, 614 trials were registered, including 92 active research. According to Globocan 2020, In Indonesia, the incidence of cancer was found to be 3,96,914 and 2,34,511 fatalities were recorded.

Participation in oncology clinical trials has expanded in recent years in the country, with a focus on illnesses such as breast cancer, lung cancer, colorectal cancer, lymphoma, paediatric cancers and leukaemia. The number of local and international pharmaceutical companies and research organisations conducting trials in the country has increased, making it an important centre for oncology clinical trials. These studies are designed to assess the safety and effectiveness of novel medications or therapies for cancer patients.

The National Agency of Drug and Food Control (BPOM) and the Ministry of Health regulate the regulatory framework for clinical trials in Indonesia. The approval procedure for a clinical experiment may be time-consuming and comprises numerous levels of evaluation. The expansion of oncology clinical trials in Indonesia is encouraging, but more efforts are required to tackle constraints such as limited resources and patient involvement. To advance the area of oncology clinical trials in Indonesia, further investment in healthcare infrastructure, research skills, and patient education is required.

indonesia oncology clinical trials market analysis

Market Dynamics

Market Growth Drivers

Many main variables are driving the increase in oncology clinical trials in Indonesia. Cancer is becoming more common in the nation, increasing the need for innovative and effective therapies. The Indonesian government has made efforts to encourage clinical trials and to create the infrastructure and talent required to support them. International collaboration has aided in the promotion and support of oncology clinical trials in the country. In certain regions, improving patient knowledge and engagement in clinical trials has resulted in greater trial enrolment. Lastly, Indonesia's huge and diversified patient population makes it an appealing place for conducting clinical trials, especially in the fields of breast cancer and leukaemia.

Market Restraints

One barrier to conducting oncology clinical trials in Indonesia is the lack of research infrastructure and resources. Many hospitals and clinics lack the requisite equipment and competence to perform extensive trials, and competent researchers and clinical trial coordinators are in limited supply. Another barrier is a lack of patient understanding and involvement in clinical trials. Many Indonesians may be unaware of clinical trials' existence or possible advantages, and cultural ideas and attitudes towards medical research might also be a barrier.

Competitive Landscape

Key Players

Pfizer Inc.
Novartis International AG
AstraZeneca plc
Roche Holding AG
Merck & Co., Inc.
Eli Lilly and Company
Sanofi S.A.
Bristol Myers Squibb Company
Kalbe Farma (IDN)
Tempo Scan Pacific (IDN)
Kimia Farma (IDN)

Notable Insights

January 2023, Indonesia has launched three programmes to improve cancer treatment. Project Extension for Community Healthcare Outcomes (ECHO), Cancer Patient Navigation (NAPAK), and a capacity-building initiative for oncology nurses
In November 2022, The Tata Memorial Foundation will train cancer patient navigators in Indonesia. As part of the Department of Atomic Energy, Government of India's Cancer Vishwam Program, the hospital developed a relationship with Roche Indonesia and the Indonesian government. It aspires to assist other developing nations in cancer care capacity-building, knowledge-sharing, and skill development.
February 2021, Kalbe of Indonesia secures a $1.1 billion contract with Genexine of South Korea for COVID and a cancer drug candidate

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Oncology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.